FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018276670> ?p ?o ?g. }

• W2018276670 endingPage "1784" @default.
• W2018276670 startingPage "1779" @default.
• W2018276670 abstract "Purpose Imexon, a pro-oxidant small molecule, has antitumor activity in preclinical models. The drug induces apoptosis through accumulation of reactive oxygen species. The purpose of this trial was to define the maximum-tolerated dose (MTD), toxicities, pharmacokinetics, and pharmacodynamics of imexon in patients with advanced cancers. Patients and Methods Forty-nine patients with metastatic cancer received intravenous imexon over 30 to 45 minutes for 5 consecutive days (one course) every other week (days 1 through 5 and 15 through 19) monthly. Doses were initially escalated using an accelerated trial design and then a modified Fibonacci method. Plasma imexon levels and six different thiols were measured by high-performance liquid chromatography assays. Results There were 13 dose levels evaluated, from 20 mg/m 2 /d to 1,000 mg/m 2 /d. The MTD recommended for phase II studies was 875 mg/m 2 /d for 5 days every 2 weeks (n = 9 patients). The two dose-limiting toxicities at 1,000 mg/m 2 /d involved grade 3 abdominal pain and fatigue and grade 4 neutropenia, which occurred in one patient each. Other common toxicities included nausea and vomiting (58%) and constipation (63%); both were managed well with prophylactic medications. One partial response was obtained in a heavily pretreated patient with non-Hodgkin's lymphoma. Pharmacokinetic studies showed dose-independent clearance, with a 95-minute mean half-life. Plasma thiol studies showed a dose- and area under the curve–dependent decrease in cystine levels 8 hours after dosing at ≥ 750 mg/m 2 /d. Conclusion The phase II recommended dose of imexon is 875 mg/m 2 /d for 5 days every other week. A decrease in plasma thiols did correlate with imexon exposure." @default.
• W2018276670 created "2016-06-24" @default.
• W2018276670 creator A5013114992 @default.
• W2018276670 creator A5013985547 @default.
• W2018276670 creator A5018050941 @default.
• W2018276670 creator A5033724353 @default.
• W2018276670 creator A5060495866 @default.
• W2018276670 creator A5064210978 @default.
• W2018276670 creator A5069690249 @default.
• W2018276670 creator A5070130751 @default.
• W2018276670 creator A5071263953 @default.
• W2018276670 creator A5073443823 @default.
• W2018276670 creator A5075801763 @default.
• W2018276670 date "2007-05-01" @default.
• W2018276670 modified "2023-09-26" @default.
• W2018276670 title "Phase I Trial of Imexon in Patients With Advanced Malignancy" @default.
• W2018276670 cites W1944778420 @default.
• W2018276670 cites W1982756904 @default.
• W2018276670 cites W1993120477 @default.
• W2018276670 cites W2008714118 @default.
• W2018276670 cites W2015112307 @default.
• W2018276670 cites W2041379917 @default.
• W2018276670 cites W2044114694 @default.
• W2018276670 cites W2053928409 @default.
• W2018276670 cites W2054735687 @default.
• W2018276670 cites W2060439771 @default.
• W2018276670 cites W2063670594 @default.
• W2018276670 cites W2064707851 @default.
• W2018276670 cites W2079594093 @default.
• W2018276670 cites W2117912906 @default.
• W2018276670 cites W2121995930 @default.
• W2018276670 cites W2129778797 @default.
• W2018276670 cites W2139248078 @default.
• W2018276670 cites W2141086589 @default.
• W2018276670 cites W2159013865 @default.
• W2018276670 cites W2163679078 @default.
• W2018276670 cites W4230136825 @default.
• W2018276670 cites W6900530 @default.
• W2018276670 doi "https://doi.org/10.1200/jco.2006.08.9672" @default.
• W2018276670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17470869" @default.
• W2018276670 hasPublicationYear "2007" @default.
• W2018276670 type Work @default.
• W2018276670 sameAs 2018276670 @default.
• W2018276670 citedByCount "54" @default.
• W2018276670 countsByYear W20182766702012 @default.
• W2018276670 countsByYear W20182766702014 @default.
• W2018276670 countsByYear W20182766702015 @default.
• W2018276670 countsByYear W20182766702016 @default.
• W2018276670 countsByYear W20182766702017 @default.
• W2018276670 countsByYear W20182766702018 @default.
• W2018276670 countsByYear W20182766702019 @default.
• W2018276670 countsByYear W20182766702020 @default.
• W2018276670 countsByYear W20182766702021 @default.
• W2018276670 countsByYear W20182766702022 @default.
• W2018276670 crossrefType "journal-article" @default.
• W2018276670 hasAuthorship W2018276670A5013114992 @default.
• W2018276670 hasAuthorship W2018276670A5013985547 @default.
• W2018276670 hasAuthorship W2018276670A5018050941 @default.
• W2018276670 hasAuthorship W2018276670A5033724353 @default.
• W2018276670 hasAuthorship W2018276670A5060495866 @default.
• W2018276670 hasAuthorship W2018276670A5064210978 @default.
• W2018276670 hasAuthorship W2018276670A5069690249 @default.
• W2018276670 hasAuthorship W2018276670A5070130751 @default.
• W2018276670 hasAuthorship W2018276670A5071263953 @default.
• W2018276670 hasAuthorship W2018276670A5073443823 @default.
• W2018276670 hasAuthorship W2018276670A5075801763 @default.
• W2018276670 hasConcept C112705442 @default.
• W2018276670 hasConcept C126322002 @default.
• W2018276670 hasConcept C2776694085 @default.
• W2018276670 hasConcept C2777063308 @default.
• W2018276670 hasConcept C2777288759 @default.
• W2018276670 hasConcept C2780580376 @default.
• W2018276670 hasConcept C71924100 @default.
• W2018276670 hasConcept C90924648 @default.
• W2018276670 hasConcept C98274493 @default.
• W2018276670 hasConceptScore W2018276670C112705442 @default.
• W2018276670 hasConceptScore W2018276670C126322002 @default.
• W2018276670 hasConceptScore W2018276670C2776694085 @default.
• W2018276670 hasConceptScore W2018276670C2777063308 @default.
• W2018276670 hasConceptScore W2018276670C2777288759 @default.
• W2018276670 hasConceptScore W2018276670C2780580376 @default.
• W2018276670 hasConceptScore W2018276670C71924100 @default.
• W2018276670 hasConceptScore W2018276670C90924648 @default.
• W2018276670 hasConceptScore W2018276670C98274493 @default.
• W2018276670 hasIssue "13" @default.
• W2018276670 hasLocation W20182766701 @default.
• W2018276670 hasLocation W20182766702 @default.
• W2018276670 hasOpenAccess W2018276670 @default.
• W2018276670 hasPrimaryLocation W20182766701 @default.
• W2018276670 hasRelatedWork W1964391114 @default.
• W2018276670 hasRelatedWork W1990335353 @default.
• W2018276670 hasRelatedWork W2002919998 @default.
• W2018276670 hasRelatedWork W2004325424 @default.
• W2018276670 hasRelatedWork W2050480145 @default.
• W2018276670 hasRelatedWork W2065005216 @default.
• W2018276670 hasRelatedWork W2154372624 @default.
• W2018276670 hasRelatedWork W2793520024 @default.
• W2018276670 hasRelatedWork W3021369409 @default.

• next